Directorate Changes

Summary by AI ^BETAClose X

Proteome Sciences plc announced that Dr. Ian Pike will step down as Chief Scientific Officer effective May 31, 2026, transitioning to a Non-Executive Director role on the same date. He has committed to providing consultancy services to ensure continuity and leverage his expertise.

Disclaimer*

Proteome Sciences PLC

01 June 2026

1 June 2026

PS_Logo_Letterhead_Word.eps

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the UK Market Abuse Regulation

Proteome Sciences plc

("Proteome Sciences" or the "Company")

Directorate Changes

The directors of Proteome Sciences plc announce that Dr Ian Pike has decided to step down from his executive role as Chief Scientific Officer with effect from 31 May 2026. To maintain continuity, Dr Pike will assume a Non-Executive Director position on the same date, whereby he has committed to provide consultancy services as required to cover his former responsibilities at Proteome Sciences. In this way the business will continue to benefit from Dr Pike's considerable expertise and industry knowledge, whilst allowing him a better time-balance for his personal life.

Proteome Sciences plc
Christopher Pearce, Executive Chairman	Tel: +44 (0) 20 7043 2116
Richard Dennis, Chief Commercial Officer
SP Angel Corporate Finance LLP (Nominated Adviser & Broker)
David Hignell/Matthew Johnson/Josh Ray (Corporate Finance) Vadim Alexandre (Corporate Broking)	Tel: +44 (0) 20 3470 0470

About Proteome Sciences plc. (www.proteomics.com)

Proteome Sciences plc is a specialist provider of contract proteomics services to enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids. SysQuant® and TMT®MS2 are unbiased methods for identifying and contextualising new targets and defining mechanisms of biological activity, with analysis using a range of depletion strategies in combination with TMTcalibrator™ providing access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. Chemoproteomics using Solvent Shift reveals the selectivity that drugs have to binding one or more proteins in the sample proteome. Targeted assay development using mass spectrometry delivers high sensitivity, interference-free biomarker analyses in situations where standard ELISA assays are not available.

Further information on the Company can be found on its website at: https://www.proteomics.com/

The Company's LEI is 213800Q62ICXANKU2986.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END